Here's a press release from DMX. Positive results. Now let us get that approval.
----------------------------------------------
Scientific validation of transdermal drug carrier
Dimethaid Research Inc DMX
Shares issued 33,021,526 Feb 25 close $3.58
Thu 26 Feb 98 News Release
Mr Peter Block reports
A comparative test on PENNSAID, a prescription lotion for the relief of
osteoarthritic joint pain and the first product using this patented
transdermal technology, found enhanced human skin absorption compared to a
control solution. Applications for marketing approval of PENNSAID have
already been made to regulatory bodies in Canada, the UK and the US. If
approved, PENNSAID would be the first topical non-steroidal
anti-inflammatory drug targeting the $4 billion North American arthritis
market. The expected benefits of this delivery system include localized
relief at the site of application, few side effects and negligible systemic
toxicity.
The researchers concluded that the carrier used in PENNSAID progressively
enhanced percutaneous absorption of diclofenac over 48 hours when used in a
multi-dose regimen as compared with an aqueous control.
Most conventional methods of drug delivery, including oral, injection, and
patch, deliver the active ingredient into the blood supply which in turn
distributes the drug throughout the entire body, including the site of
pain. This systemic distribution can lead to serious side effects such as
gastro-intestinal bleeds and even death. In contrast, topically applied
PENNSAID avoids the systemic distribution by using Dimethaid's transdermal
carrier to access the micro-circulatory system within each cell to deliver
the medication. In a continuing phase IV study in Canada, over 700
physician-investigators have prescribed PENNSAID to more than 2,400
patients in a primary care setting with the most commonly reported adverse
event being minor skin irritation in fewer than 3% of those having used the
drug. |
